journal
https://read.qxmd.com/read/38887373/alcam-mediated-cdc1-cd8-t-cells-interactions-are-suppressed-in-advanced-lung-tumors
#1
JOURNAL ARTICLE
Luciano G Morosi, Giulia M Piperno, Lucía López, Roberto Amadio, Sonal Joshi, Alessandra Rustighi, Giannino Del Sal, Federica Benvenuti
Conventional type 1 dendritic cells (cDC1) are critical regulators of anti-tumoral T-cell responses. The structure and abundance of intercellular contacts between cDC1 and CD8 T cells in cancer tissues is important to determine the outcome of the T-cell response. However, the molecular determinants controlling the stability of cDC1-CD8 interactions during cancer progression remain poorly investigated. Here, we generated a genetic model of non-small cell lung cancer crossed to a fluorescent cDC1 reporter (KP-XCR1venus ) to allow the detection of cDC1-CD8T cell clusters in tumor tissues across tumor stages...
2024: Oncoimmunology
https://read.qxmd.com/read/38887372/cd28-cd57-t-cells-from-head-and-neck-cancer-patients-produce-high-levels-of-cytotoxic-granules-and-type-ii-interferon-but-are-not-senescent
#2
JOURNAL ARTICLE
Brendan L C Kinney, Brianna Brammer, Vikash Kansal, Connor J Parrish, Haydn T Kissick, Yuan Liu, Nabil F Saba, Zachary S Buchwald, Mark W El-Deiry, Mihir R Patel, Brian J Boyce, Azeem S Kaka, Jennifer H Gross, H Michael Baddour, Amy Y Chen, Nicole C Schmitt
T lymphocytes expressing CD57 and lacking costimulatory receptors CD27/CD28 have been reported to accumulate with aging, chronic infection, and cancer. These cells are described as senescent, with inability to proliferate but enhanced cytolytic and cytokine-producing capacity. However, robust functional studies on these cells taken directly from cancer patients are lacking. We isolated these T cells and their CD27/28+ counterparts from blood and tumor samples of 50 patients with previously untreated head and neck cancer...
2024: Oncoimmunology
https://read.qxmd.com/read/38872753/improving-sting-agonist-based-cancer-therapy-by-inhibiting-the-autophagy-related-protein-vps34
#3
JOURNAL ARTICLE
Elisabetta Bartolini, Kris Van Moer, Bassam Janji
We have recently demonstrated that inhibiting VPS34 enhances T-cell-recruiting chemokines through the activation of the cGAS/STING pathway using the STING agonist ADU-S100. Combining VPS34 inhibitors with ADU-S100 increased cytokine release and improved tumor control in mouse models, suggesting a potential synergy between VPS34 inhibition and therapies based on STING agonists.
2024: Oncoimmunology
https://read.qxmd.com/read/38868078/exploring-immune-status-in-peripheral-blood-and-tumor-tissue-in-association-with-survival-in-patients-with-multi-organ-metastatic-colorectal-cancer
#4
JOURNAL ARTICLE
Lotte Bakkerus, Beatriz Subtil, Hetty J Bontkes, Elske C Gootjes, Martine Reijm, Manon Vullings, Kiek Verrijp, John-Melle Bokhorst, Carmen Woortman, Iris D Nagtegaal, Marianne A Jonker, Hans J van der Vliet, Cornelis Verhoef, Mark A J Gorris, I Jolanda M de Vries, Tanja D de Gruijl, Henk M W Verheul, Tineke E Buffart, Daniele V F Tauriello
Colorectal cancer (CRC) raises considerable clinical challenges, including a high mortality rate once the tumor spreads to distant sites. At this advanced stage, more accurate prediction of prognosis and treatment outcome is urgently needed. The role of cancer immunity in metastatic CRC (mCRC) is poorly understood. Here, we explore cellular immune cell status in patients with multi-organ mCRC. We analyzed T cell infiltration in primary tumor sections, surveyed the lymphocytic landscape of liver metastases, and assessed circulating mononuclear immune cells...
2024: Oncoimmunology
https://read.qxmd.com/read/38846085/%C3%AE-lapachone-promotes-the-recruitment-and-polarization-of-tumor-associated-neutrophils-tans-toward-an-antitumor-n1-phenotype-in-nqo1-positive-cancers
#5
JOURNAL ARTICLE
Soumya Tumbath, Lingxiang Jiang, Xiaoguang Li, Taolan Zhang, Kashif Rafiq Zahid, Ye Zhao, Hao Zhou, Zhijun Yin, Tao Lu, Shu Jiang, Yaomin Chen, Xiang Chen, Yang-Xin Fu, Xiumei Huang
NAD(P)H:quinone oxidoreductase 1 (NQO1) is overexpressed in most solid cancers, emerging as a promising target for tumor-selective killing. β-Lapachone (β-Lap), an NQO1 bioactivatable drug, exhibits significant antitumor effects on NQO1-positive cancer cells by inducing immunogenic cell death (ICD) and enhancing tumor immunogenicity. However, the interaction between β-Lap-mediated antitumor immune responses and neutrophils, novel antigen-presenting cells (APCs), remains unknown. This study demonstrates that β-Lap selectively kills NQO1-positive murine tumor cells by significantly increasing intracellular ROS formation and inducing DNA double strand breaks (DSBs), resulting in DNA damage...
2024: Oncoimmunology
https://read.qxmd.com/read/38846084/cd20-expression-regulates-cd37-levels-in-b-cell-lymphoma-implications-for-immunotherapies
#6
JOURNAL ARTICLE
Malgorzata Bobrowicz, Aleksandra Kusowska, Marta Krawczyk, Andriy Zhylko, Christopher Forcados, Aleksander Slusarczyk, Joanna Barankiewicz, Joanna Domagala, Matylda Kubacz, Michal Šmída, Lenka Dostalova, Katsiaryna Marhelava, Klaudyna Fidyt, Monika Pepek, Iwona Baranowska, Anna Szumera-Cieckiewicz, Else Marit Inderberg, Sébastien Wälchli, Monika Granica, Agnieszka Graczyk-Jarzynka, Martyna Majchrzak, Marcin Poreba, Carina Lynn Gehlert, Matthias Peipp, Malgorzata Firczuk, Monika Prochorec-Sobieszek, Magdalena Winiarska
Rituximab (RTX) plus chemotherapy (R-CHOP) applied as a first-line therapy for lymphoma leads to a relapse in approximately 40% of the patients. Therefore, novel approaches to treat aggressive lymphomas are being intensively investigated. Several RTX-resistant (RR) cell lines have been established as surrogate models to study resistance to R-CHOP. Our study reveals that RR cells are characterized by a major downregulation of CD37, a molecule currently explored as a target for immunotherapy. Using CD20 knockout (KO) cell lines, we demonstrate that CD20 and CD37 form a complex, and hypothesize that the presence of CD20 stabilizes CD37 in the cell membrane...
2024: Oncoimmunology
https://read.qxmd.com/read/38846083/hunk-as-a-key-regulator-of-tumor-associated-macrophages-in-triple-negative-breast-cancer
#7
JOURNAL ARTICLE
Nicole Ramos Solis, Anthony Cannon, Tinslee Dilday, Melissa Abt, Adrian L Oblak, Adam C Soloff, Mark H Kaplan, Elizabeth S Yeh
Triple-negative breast cancer (TNBC) lacks the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). TNBC tumors are not sensitive to endocrine therapy, and standardized TNBC treatment regimens are lacking. TNBC is a more immunogenic subtype of breast cancer, making it more responsive to immunotherapy intervention. Tumor-associated macrophages (TAMs) constitute one of the most abundant immune cell populations in TNBC tumors and contribute to cancer metastasis...
2024: Oncoimmunology
https://read.qxmd.com/read/38812571/immunogenic-oncolysis-by-tigilanol-tiglate
#8
JOURNAL ARTICLE
Jonathan G Pol, Manuela Lizarralde-Guerrero, Guido Kroemer
Tigilanol tiglate is an oncolytic small molecule that is undergoing clinical trials. A recent study revealed the capacity of this pyroptosis inducer to elicit hallmarks of immunogenic cell death. In addition, intratumoral injection of tigilanol tiglate can sensitize subcutaneous cancers to subsequent immune checkpoint inhibitors targeting CTLA-4 alone or in combination with PD-1.
2024: Oncoimmunology
https://read.qxmd.com/read/38812570/clinically-relevant-gabarap-deficiency-abrogates-bortezomib-induced-immunogenic-cell-death-in-multiple-myeloma
#9
JOURNAL ARTICLE
Liwei Zhao, Zhe Shen, Guido Kroemer, Oliver Kepp
Recently, it was revealed that the high-risk, poor-prognosis downregulation of GABA type A receptor-associated protein (GABARAP) causes a defect in both autophagy and surface exposure of calreticulin (CALR) in multiple myeloma (MM) cells responding to bortezomib. Hence, GABARAP-defective MM cells fail to undergo immunogenic cell death.
2024: Oncoimmunology
https://read.qxmd.com/read/38812569/cxcl10-and-il15-co-expressing-chimeric-antigen-receptor-t-cells-enhance-anti-tumor-effects-in-gastric-cancer-by-increasing-cytotoxic-effector-cell-accumulation-and-survival
#10
JOURNAL ARTICLE
Siyue Nie, Yujie Song, Kun Hu, Wei Zu, Fengjiao Zhang, Lixia Chen, Qiang Ma, Zishan Zhou, Shunchang Jiao
Chimeric antigen receptor (CAR) T cells have demonstrated outstanding therapeutic success in hematological malignancies. Yet, their efficacy against solid tumors remains constrained due to inadequate infiltration of cytotoxic T and CAR-T cells in the tumor microenvironment (TME), a factor correlated with poor prognosis in patients with solid tumors. To overcome this limitation, we engineered CAR-T cells to secrete CXCL10 and IL15 (10 × 15 CAR-T), which sustain T cell viability and enhance their recruitment, thereby amplifying the long-term cytotoxic capacity of CAR-T cells in vitro...
2024: Oncoimmunology
https://read.qxmd.com/read/38798746/peripheral-cx3cr1-t-cells-combined-with-pd-1-blockade-therapy-potentiates-the-anti-tumor-efficacy-for-lung-cancer
#11
JOURNAL ARTICLE
Congcong Li, Zhen Zhang, Qianfeng Cai, Qitai Zhao, Han Wu, JunRu Li, Yaqing Liu, Xuan Zhao, Jinyan Liu, Yu Ping, Jiqi Shan, Shengli Yang, Yi Zhang
Identifying tumor-relevant T cell subsets in the peripheral blood (PB) has become a potential strategy for cancer treatment. However, the subset of PB that could be used to treat cancer remains poorly defined. Here, we found that the CX3CR1+ T cell subset in the blood of patients with lung cancer exhibited effector properties and had a higher TCR matching ratio with tumor-infiltrating lymphocytes (TILs) compared to CX3CR1- T cells, as determined by paired single-cell RNA and TCR sequencing. Meanwhile, the anti-tumor activities, effector cytokine production, and mitochondrial function were enhanced in CX3CR1+ T cells both in vitro and in vivo ...
2024: Oncoimmunology
https://read.qxmd.com/read/38778816/hif2a-mediates-lineage-transition-to-aggressive-phenotype-of-cancer-associated-fibroblasts-in-lung-cancer-brain-metastasis
#12
JOURNAL ARTICLE
Muyuan You, Minjie Fu, Zhewei Shen, Yuan Feng, Licheng Zhang, Xianmin Zhu, Zhengping Zhuang, Ying Mao, Wei Hua
Brain metastasis is the most devasting form of lung cancer. Recent studies highlight significant differences in the tumor microenvironment (TME) between lung cancer brain metastasis (LCBM) and primary lung cancer, which contribute significantly to tumor progression and drug resistance. Cancer-associated fibroblasts (CAFs) are the major component of pro-tumor TME with high plasticity. However, the lineage composition and function of CAFs in LCBM remain elusive. By reanalyzing single-cell RNA sequencing (scRNA-seq) data (GSE131907) from lung cancer patients with different stages of metastasis comprising primary lesions and brain metastasis, we found that CAFs undergo distinctive lineage transition during LCBM under a hypoxic situation, which is directly driven by hypoxia-induced HIF-2α activation...
2024: Oncoimmunology
https://read.qxmd.com/read/38746870/characterization-of-innate-lymphoid-cell-subsets-infiltrating-melanoma-and-epithelial-ovarian-tumors
#13
JOURNAL ARTICLE
Douglas C Chung, Maryam Ghaedi, Kathrin Warner, Azin Sayad, Samuel D Saibil, Marcus Q Bernardini, Blaise A Clarke, Patricia A Shaw, Marcus O Butler, Alexandra Easson, Sorana Morrissy, Ben X Wang, Linh Nguyen, Pamela S Ohashi, Nicolas Jacquelot
The innate lymphoid cell (ILC) family is composed of heterogeneous innate effector and helper immune cells that preferentially reside in tissues where they promote tissue homeostasis. In cancer, they have been implicated in driving both pro- and anti-tumor responses. This apparent dichotomy highlights the need to better understand differences in the ILC composition and phenotype within different tumor types that could drive seemingly opposite anti-tumor responses. Here, we characterized the frequency and phenotype of various ILC subsets in melanoma metastases and primary epithelial ovarian tumors...
2024: Oncoimmunology
https://read.qxmd.com/read/38746869/cpt1c-positive-cancer-associated-fibroblast-facilitates-immunosuppression-through-promoting-il-6-induced-m2-like-phenotype-of-macrophage
#14
JOURNAL ARTICLE
Rongyuan Wei, Junquan Song, Hongda Pan, Xiaowen Liu, Jianpeng Gao
Cancer-associated fibroblasts (CAFs) exhibit remarkable phenotypic heterogeneity, with specific subsets implicated in immunosuppression in various malignancies. However, whether and how they attenuate anti-tumor immunity in gastric cancer (GC) remains elusive. CPT1C, a unique isoform of carnitine palmitoyltransferase pivotal in regulating fatty acid oxidation, is briefly indicated as a protumoral metabolic mediator in the tumor microenvironment (TME) of GC. In the present study, we initially identified specific subsets of fibroblasts exclusively overexpressing CPT1C, hereby termed them as CPT1C+ CAFs...
2024: Oncoimmunology
https://read.qxmd.com/read/38737794/expression-of-cd39-is-associated-with-t-cell-exhaustion-in-ovarian-cancer-and-its-blockade-reverts-t-cell-dysfunction
#15
JOURNAL ARTICLE
Witt Marius, Oliveira-Ferrer Leticia, Koch-Nolte Friedrich, Menzel Stephan, Hell Louisa, Sturmheit Tabea, Seubert Elisa, Weimer Pauline, Ding Yi, Minyue Qi, Schmalfeldt Barbara, Bokemeyer Carsten, Fiedler Walter, Wellbrock Jasmin, Brauneck Franziska
Immune exhaustion is a hallmark of ovarian cancer. Using multiparametric flow cytometry, the study aimed to analyze protein expression of novel immunological targets on CD3+ T cells isolated from the peripheral blood ( n  = 20), malignant ascites ( n  = 16), and tumor tissue ( n  = 6) of patients with ovarian cancer (OVCA). The study revealed an increased proportion of effector memory CD8+ T cells in OVCA tissue and malignant ascites. An OVCA-characteristic PD-1high CD8+ T cell population was detected, which differed from PD-1low CD8+ T cells by increased co-expression of TIGIT, CD39, and HLA-DR...
2024: Oncoimmunology
https://read.qxmd.com/read/38737793/memory-like-differentiation-enhances-nk-cell-responses-against-colorectal-cancer
#16
JOURNAL ARTICLE
Nancy D Marin, Michelle Becker-Hapak, Wilbur M Song, Quazim A Alayo, Lynne Marsala, Naomi Sonnek, Melissa M Berrien-Elliott, Mark Foster, Jennifer A Foltz, Jennifer Tran, Pamela Wong, Celia C Cubitt, Patrick Pence, Kimberly Hwang, Alice Y Zhou, Miriam T Jacobs, Timothy Schappe, David A Russler-Germain, Ryan C Fields, Matthew A Ciorba, Todd A Fehniger
Metastatic (m) colorectal cancer (CRC) is an incurable disease with a poor prognosis and thus remains an unmet clinical need. Immune checkpoint blockade (ICB)-based immunotherapy is effective for mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) mCRC patients, but it does not benefit the majority of mCRC patients. NK cells are innate lymphoid cells with potent effector responses against a variety of tumor cells but are frequently dysfunctional in cancer patients. Memory-like (ML) NK cells differentiated after IL-12/IL-15/IL-18 activation overcome many challenges to effective NK cell anti-tumor responses, exhibiting enhanced recognition, function, and in vivo persistence...
2024: Oncoimmunology
https://read.qxmd.com/read/38737792/distinct-autoantibody-profiles-across-checkpoint-inhibitor-types-and-toxicities
#17
RANDOMIZED CONTROLLED TRIAL
Hong Mu-Mosley, Mitchell S von Itzstein, Farjana Fattah, Jialiang Liu, Chengsong Zhu, Yang Xie, Edward K Wakeland, Jason Y Park, Brad S Kahl, Catherine S Diefenbach, David E Gerber
Immune checkpoint inhibitors (ICI) are increasingly used in combination. To understand the effects of different ICI categories, we characterized changes in circulating autoantibodies in patients enrolled in the E4412 trial (NCT01896999) of brentuximab vedotin (BV) plus ipilimumab, BV plus nivolumab, or BV plus ipilimumab-nivolumab for Hodgkin Lymphoma. Cycle 2 Day 1 (C2D1) autoantibody levels were compared to pre-treatment baseline. Across 112 autoantibodies tested, we generally observed increases in ipilimumab-containing regimens, with decreases noted in the nivolumab arm...
2024: Oncoimmunology
https://read.qxmd.com/read/38694625/principles-of-risk-assessment-in-colon-cancer-immunity-is-key
#18
REVIEW
Assia Hijazi, Jérôme Galon
In clinical practice, the administration of adjuvant chemotherapy (ACT) following tumor surgical resection raises a critical dilemma for stage II colon cancer (CC) patients. The prognostic features used to identify high-risk CC patients rely on the pathological assessment of tumor cells. Currently, these factors are considered for stratifying patients who may benefit from ACT at early CC stages. However, the extent to which these factors predict clinical outcomes ( i.e . recurrence, survival) remains highly controversial, also uncertainty persists regarding patients' response to treatment, necessitating further investigation...
2024: Oncoimmunology
https://read.qxmd.com/read/38686178/immune-checkpoint-therapy-responders-display-early-clonal-expansion-of-tumor-infiltrating-lymphocytes
#19
JOURNAL ARTICLE
Joel Kidman, Rachael M Zemek, John-William Sidhom, Debora Correa, Nicola Principe, Fezaan Sheikh, Vanessa S Fear, Catherine A Forbes, Abha Chopra, Louis Boon, Ayham Zaitouny, Emma de Jong, Robert A Holt, Matt Jones, Michael J Millward, Timo Lassmann, Alistair R R Forrest, Anna K Nowak, Mark Watson, Richard A Lake, W Joost Lesterhuis, Jonathan Chee
Immune checkpoint therapy (ICT) causes durable tumour responses in a subgroup of patients, but it is not well known how T cell receptor beta (TCRβ) repertoire dynamics contribute to the therapeutic response. Using murine models that exclude variation in host genetics, environmental factors and tumour mutation burden, limiting variation between animals to naturally diverse TCRβ repertoires, we applied TCRseq, single cell RNAseq and flow cytometry to study TCRβ repertoire dynamics in ICT responders and non-responders...
2024: Oncoimmunology
https://read.qxmd.com/read/38659649/the-potential-role-of-cmc1-as-an-immunometabolic-checkpoint-in-t-cell-immunity
#20
JOURNAL ARTICLE
Yuwen Chen, Jie Gao, Mingyue Ma, Ke Wang, Fangming Liu, Feiyu Yang, Xin Zou, Zhouli Cheng, Duojiao Wu
T cell immunity is critical for human defensive immune response. Exploring the key molecules during the process provides new targets for T cell-based immunotherapies. CMC1 is a mitochondrial electron transport chain (ETC) complex IV chaperon protein. By establishing in-vitro cell culture system and Cmc1 gene knock out mice, we evaluated the role of CMC1 in T cell activation and differentiation. The B16-OVA tumor model was used to test the possibility of targeting CMC1 for improving T cell anti-tumor immunity...
2024: Oncoimmunology
journal
journal
43770
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.